โ† All deals

NEKTAR THERAPEUTICS

Public Equity (NASDAQ)BiotechnologyImmunotherapyPublic Company
๐Ÿ“ San Francisco, California, United Statesโ€ข Founded 1990
StreetZero Signal 49
Be the first to signal interest

About NEKTAR THERAPEUTICS

Nektar Therapeutics is a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy. Headquartered in San Francisco, California, the public company (Nasdaq: NKTR) was founded in 1990 and operates with a B2B business model. It is advancing candidates such as rezpegaldesleukin in Phase III trials for atopic dermatitis and alopecia areata, following prior partnerships including one with Bristol Myers Squibb.

LATEST FUNDINGRule 144
$15K
Announced 2026-11-17
TOTAL RAISED2.10B USD
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for NEKTAR THERAPEUTICS.

Free plan includes 3 full deal profiles every month.

Key highlights

  • Raised $250M via public offering in April 2026 to fund Phase III trials for rezpegaldesleukin.
  • Completed $30M private placement with TCGX in March 2024.
  • Public company on Nasdaq (NKTR) with prior partnership valued at $3.6B with Bristol Myers Squibb.
  • Total funding across rounds reached $2.10B with investors including New Enterprise Associates and AstraZeneca.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account